Jason M Guernon

This inventor holds 10 USPTO granted patents and 3 published patent applications and 8 EPO patents. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2007-2023.

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 100.0

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 74(Granted Patents)

Location History:

Hamden, CT (US) (2007)
Moodus, CT (US) (2013 - 2016)
Pipersville, PA (US) (2020 - 2023)

Company Filing History:

10 out of 3,737

Bristol-Myers Squibb Compnay

patents

Years Active: 2007-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11618753 - Aminopyrrolotriazines as kinase inhibitors (2023-04-04),

2. 11440913 - Aminoimidazopyridazines as kinase inhibitors (2022-09-13),

3. 10836758 - Acyl sulfonamide NaV1.7 inhibitors (2020-11-17),

4. 9475784 - 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production (2016-10-25),

5. 8710061 - Compounds for the reduction of β-amyloid production (2014-04-29),

6. 8637525 - Compounds for the reduction of beta-amyloid production (2014-01-28),

7. 8637523 - Compounds for the reduction of beta-amyloid production (2014-01-28),

8. 8486952 - Compounds for the reduction of β-amyloid production (2013-07-16),

9. 8349880 - Bicyclic compounds for the reduction of beta-amyloid production (2013-01-08),

10. 7273866 - 2-aryl thiazole derivatives as KCNQ modulators (2007-09-25),

Title: Jason M Guernon: Innovator in Kinase Inhibitors

Introduction

Jason M Guernon is a prominent inventor based in Moodus, Connecticut, known for his significant contributions to the field of kinase inhibitors. With a total of 10 patents to his name, Guernon has made remarkable strides in developing compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Guernon has developed "Aminopyrrolotriazines as kinase inhibitors." This patent discloses compounds that are useful as kinase modulators, particularly in the modulation of RIPK1. The methods outlined in this patent provide innovative approaches for treating conditions related to necrosis and inflammation, among other indications. Another notable patent is "Aminoimidazopyridazines as kinase inhibitors," which describes compounds that serve as kinase modulators, including RIPK1 modulation. These compounds encompass various forms, including enantiomers and diastereomers, and are designed for pharmaceutical applications.

Career Highlights

Guernon is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research and development efforts in the pharmaceutical industry. His work focuses on creating innovative solutions that address critical health challenges.

Collaborations

Throughout his career, Guernon has collaborated with esteemed colleagues, including Yong-Jin Wu and John E Macor. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Jason M Guernon stands out as a key figure in the development of kinase inhibitors, with a strong portfolio of patents that reflect his dedication to advancing medical science. His contributions are paving the way for new treatments and therapies that could significantly impact patient care.